当前位置: 首页 >> 检索结果
共有 4331 条符合本次的查询结果, 用时 4.3011522 秒

3881. High diagnostic yield despite a lower completion rates for inpatient versus outpatient colon and pan-intestinal capsule endoscopy: a nested case-control study.

作者: Charlene Deane.;Caroline Walker.;Barbara Ryan.;Anthony O'Connor.;Sarah O'Donnell.;Niall Breslin.;Deirdre McNamara.
来源: BMC Gastroenterol. 2023年23卷1期61页
Increased familiarity with capsule endoscopy (CE) has been associated with a growing demand for urgent inpatient procedures. Limited data exists comparing the effect of admission status on colon capsule (CCE) and pan-intestinal capsule (PIC) performance. We aimed to compare the quality of inpatient versus outpatient CCE and PIC studies.

3882. Impacts of neoadjuvant therapy on the number of dissected lymph nodes in esophagogastric junction cancer patients.

作者: Qi Wang.;Jin-Tong Ge.;Hua Wu.;Sheng Zhong.;Qing-Quan Wu.
来源: BMC Gastroenterol. 2023年23卷1期64页
Neoadjuvant therapy favors the prognosis of various cancers, including esophagogastric junction cancer (EGC). However, the impacts of neoadjuvant therapy on the number of dissected lymph nodes (LNs) have not yet been evaluated in EGC.

3883. Survival analysis and individualized prediction of survival benefit for pancreatic signet ring cell carcinoma: a population study based on the SEER database.

作者: Duorui Nie.;Jing Yang.;Hao Zheng.;Guihua Lai.;Fei Wang.;Jianxiong Cao.;Chun Gong.
来源: BMC Gastroenterol. 2023年23卷1期62页
This study aimed to compare the incidence, clinicopathological characteristics and survival results of pancreatic signet ring cell carcinoma (PSRCC) and pancreatic adenocarcinomas (PDAC), as well as to analyze the clinical characteristics related to the overall survival (OS) of PSRCC, and to establish an effective prognostic nomogram to predict the risks associated with patient outcomes.

3884. Potential utility of a multi-component coagulation factor panel to calculate MELD scores and assess the risk of portal vein thrombosis in chronic liver disease.

作者: Clayton S Lewis.;Khurram Bari.;Changchun Xie.;Kenneth E Sherman.;Marc Vasse.;Patrick Van Dreden.;Vladimir Y Bogdanov.
来源: BMC Gastroenterol. 2023年23卷1期65页
Current quantitative approaches to assess chronic liver disease (CLD) severity have limitations. Further, portal vein thrombosis (PVT) pre-liver transplant (LT) is a major contributor to morbidity in CLD; the means of detecting and/or predicting PVT are limited. We sought to explore whether plasma coagulation factor activity levels can serve as a substitute for prothrombin time/international normalized ratio (PT/INR) in the Model for End-stage Liver Disease (MELD), and/or help assess the risk of PVT.

3885. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.

作者: Yoshinobu Saito.;Dingzi Yin.;Naoto Kubota.;Xiaobo Wang.;Aveline Filliol.;Helen Remotti.;Ajay Nair.;Ladan Fazlollahi.;Yujin Hoshida.;Ira Tabas.;Kirk J Wangensteen.;Robert F Schwabe.
来源: Gastroenterology. 2023年164卷7期1279-1292页
Despite recent progress, long-term survival remains low for hepatocellular carcinoma (HCC). The most effective HCC therapies target the tumor immune microenvironment (TIME), and there are almost no therapies that directly target tumor cells. Here, we investigated the regulation and function of tumor cell-expressed Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) in HCC.

3886. A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.

作者: Xin Guo.;Yunhua Peng.;Qiying Song.;Jiangpeng Wei.;Xinxin Wang.;Yi Ru.;Shenhui Xu.;Xin Cheng.;Xiaohua Li.;Di Wu.;Lubin Chen.;Bo Wei.;Xiaohui Lv.;Gang Ji.
来源: Gastroenterology. 2023年165卷2期402-413.e13页
Diagnosing gastric cancer (GC) while the disease remains eligible for surgical resection is challenging. In view of this clinical challenge, novel and robust biomarkers for early detection thus improving prognosis of GC are necessary. The present study is to develop a blood-based long noncoding RNA (LR) signature for the early-detection of GC.

3887. Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.

作者: Magdalena Espinoza.;Maishara Muquith.;Mir Lim.;Hao Zhu.;Amit G Singal.;David Hsiehchen.
来源: Gastroenterology. 2023年165卷1期286-288.e4页

3888. Observation of the effect of predictive nursing intervention on the care of complications in patients with nephrotic syndrome.

作者: Yongjuan Xu.;Weiwei Wang.;Mei Li.
来源: Minerva Gastroenterol (Torino). 2023年69卷3期440-442页

3889. Evaluation of the effectiveness of health education pathway in the care of patients with gestational diabetes mellitus.

作者: Xiao Lu.;Yongjuan Xu.;Hongmei Wang.
来源: Minerva Gastroenterol (Torino). 2023年69卷3期442-444页

3890. Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease.

作者: Gabriele Castelnuovo.;Nuria Perez-Diaz-Del-Campo.;Marta Guariglia.;Irene Poggiolini.;Angelo Armandi.;Chiara Rosso.;Gian P Caviglia.;Elisabetta Bugianesi.
来源: Minerva Gastroenterol (Torino). 2024年70卷4期446-453页
Non-alcoholic steatohepatitis (NASH) is a high-prevalence, rapidly growing form of non-alcoholic fatty liver disease (NAFLD), which is closely linked to obesity and metabolic disorders. Gut microbiota has been increasingly recognized as a key factor in the onset of NAFLD in recent years. The liver can be strongly influenced by changes in the gut microbiota through the portal vein, giving the gut-liver axis a very important role in understanding the pathophysiology of liver diseases. A healthy intestinal barrier is characterized by selective permeability to nutrients, metabolites, water and bacterial products and its impairment may be a predisposing or aggravating condition for the progression of NAFLD. In most cases, NAFLD patients follow a Western diet pattern, which is closely linked to obesity and associated metabolic diseases, promoting inflammation, structural and behavioral changes in the gut microbiota. In fact, factors such as age, gender, genetic or environmental factors may induce a dysbiotic microbiota that promotes epithelial barrier dysfunction and increased intestinal permeability, favoring the progression of NAFLD. In this context, new dietary approaches, such as prebiotics, are emerging to prevent disease and maintain health. In this review, we reported the role of the gut-liver axis in the pathogenesis of NAFLD and investigated the potential therapeutic effect of prebiotics on the enhancement of intestinal barrier dysfunction, hepatic steatosis and, consequently, the progression of NAFLD.

3891. Food elimination diet is a viable alternative therapy for eosinophilic esophagitis responsive to proton pump inhibitors.

作者: Twan Sia.;Evan Cunningham.;Megan Miller.;Rebecca Nitschelm.;Riki Tanaka.;Taylor Epstein.;Kendall Garrett.;Amy Huang.;Daniel Pak.;Ally Scheve.;John Leung.
来源: BMC Gastroenterol. 2023年23卷1期60页
First-line treatment of eosinophilic esophagitis (EoE) includes monotherapy with proton-pump inhibitors (PPIs), food elimination diet (FED), or topical corticosteroids. Current guidelines suggest patients with EoE should continue any responsive first-line monotherapies. However, the efficacy of FED monotherapy in patients with EoE responsive to PPI monotherapy has not been well studied. Our study aimed to investigate how attempting FED monotherapy after experiencing remission of EoE after PPI monotherapy influenced long-term EoE management.

3892. Immediate postoperative parenteral anticoagulant therapy in patients with mesenteric ischemia after intestinal resection: a retrospective cohort study at a single institute.

作者: Hsiao-Tien Liu.;Chia-Yu Lai.;Jian-Jhou Liao.;Yi-Ju Chen.;Shao-Bin Cheng.;Cheng-Chung Wu.
来源: BMC Gastroenterol. 2023年23卷1期56页
Bowel gangrene represents a major fatal event in acute mesenteric ischemia. Intestinal resection is inevitable in patients with peritonitis and bowel gangrene. This retrospective study aimed to elucidate the benefit of postoperative parenteral anticoagulation in patients with intestinal resection.

3893. Development of an immune-related gene prognostic risk model and identification of an immune infiltration signature in the tumor microenvironment of colon cancer.

作者: Mengdi Hao.;Huimin Li.;Meng Yi.;Yubing Zhu.;Kun Wang.;Yin Liu.;Xiaoqing Liang.;Lei Ding.
来源: BMC Gastroenterol. 2023年23卷1期58页
Colon cancer is a common and highly malignant tumor. Its incidence is increasing rapidly with poor prognosis. At present, immunotherapy is a rapidly developing treatment for colon cancer. The aim of this study was to construct a prognostic risk model based on immune genes for early diagnosis and accurate prognostic prediction of colon cancer.

3894. Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn's disease.

作者: Ye Ma.;Runfeng Zhang.;Wei Liu.;Yinghao Sun.;Jingnan Li.;Hong Yang.;Hong Lv.;Yue Li.;Bei Tan.;Xiyu Sun.;Jiaming Qian.;Ji Li.
来源: BMC Gastroenterol. 2023年23卷1期57页
Enteric fistula is one of the penetrating features in Crohn's disease (CD). This study aimed to clarify the prognostic factors for the efficacy of infliximab (IFX) treatment in luminal fistulizing CD patients.

3895. Factors associated with delayed reporting for surgical care among patients with surgical acute abdomen attended at Muhimbili National Hospital: Tanzania.

作者: Maryam Hamdan.;Xu Yang.;M Mavura.;Mohammed Saleh.;George Kannani.;Kang Haonan.;Abdullah Al-Danakh.;Xu Zhaohui.;Gong Zezhong.;Ri Hyokju.;Boureima Amado.;Ren Yanying.;Chen Xin.
来源: BMC Gastroenterol. 2023年23卷1期59页
Surgical acute abdomen is a sudden onset of severe abdominal symptoms (pain, vomiting, constipation etc.) indicative of a possible life-threatening intra-abdominal pathology, with most cases requiring immediate surgical intervention. Most studies from developing countries have focused on complications related to delayed diagnosis of specific abdominal problems like intestinal obstruction or acute appendicitis and only a few studies have assessed factors related to the delay in patients with acute abdomen. This study focused on the time from the onset of a surgical acute abdomen to presentation to determine factors that led to delayed reporting among these patients at the Muhimbili National Hospital (MNH) and aimed to close the knowledge gap on the incidence, presentation, etiology, and death rates for acute abdomen in Tanzania.

3896. Fenofibrate Improves Outcomes in Ischemic Cholangiopathy After Liver Transplantation.

作者: Channa R Jayasekera.;Michele Barnhill.;David M Chascsa.;Bashar Aqel.;Elizabeth J Carey.;Hugo E Vargas.
来源: Gastroenterology. 2023年164卷7期1321-1323.e2页

3897. Factor Analysis of the Rome IV Criteria for Major Disorders of Gut-Brain Interaction (DGBI) Globally and Across Geographical, Sex, and Age Groups.

作者: Jóhann P Hreinsson.;Hans Törnblom.;Jan Tack.;Douglas A Drossman.;William E Whitehead.;Shrikant I Bangdiwala.;Ami D Sperber.;Olafur S Palsson.;Magnus Simrén.
来源: Gastroenterology. 2023年164卷7期1211-1222页
The Rome criteria are widely accepted for diagnosing disorders of gut-brain interaction, but their global applicability has been debated. This study aimed to evaluate the validity of the Rome IV criteria by factor analysis globally, across geographical regions, by sex, and by age groups.

3898. Diarrhea Associated With Sigmoid Cancer-As Usual?

作者: Jakob Garbe.;Jonas Rosendahl.;Sebastian Krug.
来源: Gastroenterology. 2023年165卷3期e10-e13页

3899. An Unusual Case of Lower Gastrointestinal Hemorrhage.

作者: Shanshan Xiong.;Sinan Lin.;Ren Mao.
来源: Gastroenterology. 2023年165卷3期e17-e19页

3900. Hiding in Plain Sight.

作者: Alexa M Choy.;Huaibin Mabel Ko.;Maureen R Kelly.;Chip A Bowman.;Daniel Green.;Daniel E Freedberg.
来源: Gastroenterology. 2023年165卷3期e14-e16页
共有 4331 条符合本次的查询结果, 用时 4.3011522 秒